January 03, 2024

Important Update on Listing Status and Strategic Direction

December 13, 2023

Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

November 21, 2023

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth

November 14, 2023

Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs

November 13, 2023

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update

September 26, 2023

Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.

September 18, 2023

Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference

September 14, 2023

Nemaura Medical Provides Update on Nasdaq Compliance Status and Process

September 13, 2023

Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program

September 12, 2023

Nemaura Medical Announces Participation at HLTH 2023, Las Vegas

September 11, 2023

Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results

August 17, 2023

Nemaura Medical Announces SFDA Approval of sugarBEAT®

August 14, 2023

Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update

August 11, 2023

Nemaura Medical Secures $6.5m in Non-Dilutive Funding

July 14, 2023

Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023

June 27, 2023

Nemaura Medical Scales-Up Pilot Expansion of proBEAT™; 56 Corporations in the U.S. Signed Up for Pilots in June 2023

June 22, 2023

Nemaura Medical to Participate at the Collision Conference in Toronto June 26-29, 2023

June 15, 2023

Nemaura Medical to Exhibit and Provide Live Product Demonstrations of Its Non-invasive Glucose Sensor at the 83rd Scientific Sessions of the American Diabetes Association June 23-26, 2023

March 21, 2023

Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton

March 15, 2023

Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement

March 09, 2023

Nemaura Medical Announces Receipt of Notice from Nasdaq

February 24, 2023

Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update

February 16, 2023

Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference

January 31, 2023

Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

January 27, 2023

Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

January 26, 2023

Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet

January 26, 2023

Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet

January 24, 2023

Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants

January 11, 2023

Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference

December 01, 2022

Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022

November 29, 2022

Nemaura Commences Pilot Program of Miboko with the NHS in the United Kingdom

November 15, 2022

Nemaura Medical Reports Fiscal Second Quarter 2023 Results and Provides Business Update

November 11, 2022

Nemaura Medical to Present at the Bernstein 2ND Annual CGM Disruptors Conference

November 04, 2022

Nemaura Medical, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

October 12, 2022

Nemaura Receives Provisional Purchase Order from Middle East Licensee TPMENA

October 04, 2022

Nemaura Medical to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

September 27, 2022

60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago

September 27, 2022

Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.

September 06, 2022

Nemaura Medical to Present at the 24th Annual H.C. Wainwright Global Investment Conference

August 15, 2022

Nemaura Medical Reports Fiscal First Quarter 2023 Results and Provides Business Update

July 21, 2022

Nemaura Medical Granted UK Trademark “Meta Score,” a Digital Biomarker Term for its Metabolic Health Program

June 30, 2022

Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022

May 23, 2022

Nemaura Medical Strengthens Balance Sheet with Further Non-Dilutive Funding

May 19, 2022

Nemaura Medical to Present at the H.C. Wainwright Global Hybrid Investment Conference

May 17, 2022

MySugarWatch Continues Large-Scale Awareness Campaign Around Nemaura Medical’s sugarBEAT Non-Invasive Continuous Glucose Monitor Commencing Direct-to-Consumer Campaign in Daily Mail

May 03, 2022

MySugarWatch Launches Physician-Focused Ads in MIMS As Part of Large-Scale Awareness Campaign Around Nemaura Medical’s sugarBEAT Non-Invasive Continuous Glucose Monitor

April 25, 2022

Nemaura Medical to Present at the Planet MicroCap Showcase 2022

March 24, 2022

Nemaura Medical to Present at the Maxim Group 2022 Virtual Growth Conference

February 28, 2022

Nemaura Medical Wins Innovation Awards

February 14, 2022

Nemaura Medical Announces Fiscal Third Quarter 2022 Financial Results and Provides Business Update